Solid Biosciences Inc.
General ticker "SLDB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $279.6M (TTM average)
Solid Biosciences Inc. follows the US Stock Market performance with the rate: 46.6%.
Estimated limits based on current volatility of 4.6%: low 5.30$, high 5.81$
Factors to consider:
- Total employees count: 100 (+13.6%) as of 2024
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Economic downturns and volatility, Geopolitical risks, Acquisition/divestiture risks
- Current price 53.7% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.71$, 5.97$]
- 2025-12-31 to 2026-12-31 estimated range: [1.00$, 3.56$]
Financial Metrics affecting the SLDB estimates:
- Positive: with PPE of -1.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -59.34 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Positive: -14.19 < Investing cash flow per share per price, % of -9.54
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 72.75 > 64.17
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term SLDB quotes
Long-term SLDB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $8.09MM | $0.00MM | $0.00MM |
| Operating Expenses | $114.55MM | $104.25MM | $129.73MM |
| Operating Income | $-106.45MM | $-104.25MM | $-129.73MM |
| Non-Operating Income | $20.47MM | $8.24MM | $5.03MM |
| Interest Expense | $0.00MM | $0.44MM | $0.34MM |
| R&D Expense | $78.42MM | $76.56MM | $96.43MM |
| Income(Loss) | $-85.98MM | $-96.02MM | $-124.70MM |
| Profit(Loss)* | $-85.98MM | $-96.02MM | $-124.70MM |
| Stockholders Equity | $211.67MM | $126.48MM | $137.25MM |
| Assets | $260.25MM | $164.94MM | $188.66MM |
| Operating Cash Flow | $-97.98MM | $-94.18MM | $-100.01MM |
| Capital expenditure | $3.02MM | $1.51MM | $0.65MM |
| Investing Cash Flow | $59.16MM | $9.69MM | $-16.09MM |
| Financing Cash Flow | $74.83MM | $3.12MM | $122.44MM |
| Earnings Per Share** | $-10.10 | $-4.83 | $-3.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.